Navigation Links
Nyer Medical Group, Inc. Reports Revenues of $18.9 Million With Net Loss of $.16 Per Share for 3rd Quarter of Fiscal Year 2008
Date:5/22/2008

BANGOR, Maine, May 22 /PRNewswire-FirstCall/ -- Nyer Medical Group, Inc. (Nasdaq: NYER) reported results for the third quarter of fiscal year 2008. Revenues for the three months ended March 31, 2008 increased $1.55 million or 8.9% to $18.92 million from $17.38 million as reported for the same period last year. Net loss for the three months ended March 31, 2008 was $615,892 or $.16 per share as compared to a net loss of $67,919 or $.02 per share for the same period ended March 31, 2007. The net loss reflects costs related to the acquisition of the remaining 20% minority interest in D.A.W. and the change in control of the Company, totaling approximately $721,000 or $.18 per share for the three months ended March 31, 2008. This was primarily due to the purchase of Class A and B (Series 1) Preferred Stock of $400,000; legal expense of $186,000 and a severance charge attributable to the non-renewal of the former chief executive officer's employment contract of $118,000.

The pharmacies segment's revenues increased $1.79 million to $17.94 million or 11.1% for the three months ended March 31, 2008 as compared to $16.15 million for the three months ended March 31, 2007. This was due to an 8.5% increase in the number of prescriptions dispensed at stores open more than one-year, the acquisition of a pharmacy in July 2007 and the addition of two new pharmacies, in April and December 2007, respectively. Stores open more than one year experienced a 5.4% growth in revenue. The pharmacies recognize revenues both from the sale of prescription medications and other products as well as through dispensing fee revenue derived through the dispensing of inventory owned by Federally Qualified Health Centers ("FQHCs") pursuant to Pharmacy Management Services Contracts entered into by the pharmacies with various FQHCs. The dollar growth in the pharmacies segment's revenues does not directly correlate with the growth in prescription dispensing due to a significant increase in the utilization of generic drugs which typically have a significantly lower selling price.

"We are pleased to have successfully concluded the acquisition of the remaining interest in the pharmacy segment and to have concluded the buyout of the control position of the Nyer family during the quarter ended March 31st," stated President and CEO Mark Dumouchel. "Going forward, the company will focus on capitalizing on both existing and developing growth opportunities in pharmacy niche businesses as well as further broadening our base of retail locations. We are additionally continuing to establish relationships within the Health Center Community to further expand our dispensing activity within the federal 340B prescription drug pricing program." Dumouchel further stated, "We anticipate further consolidation of expenses as we eliminate duplication in general and administrative expenses necessitated by the prior parent/subsidiary relationship. We are in the midst of a thorough examination and elimination of businesses that are not consistent with our strategic direction and profit objectives."

About Nyer Medical Group

Nyer Medical Group, Inc. is a holding company that through its subsidiaries operates pharmacies in the greater Boston area and a medical products business that distributes and markets medical equipment and supply products to hospitals, physicians and nursing homes using relationship-based telemarketing, direct sales personnel, catalogs and the Internet. These orders are filled by the company's distribution centers located in New England and South Florida.

For further information contact Mark Dumouchel (508) 429-8506, ext. 16.

Safe Harbor for Forward-Looking Statements

Certain statements contained in this press release are forward-looking in nature within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements are generally identified by the inclusion of phrases such as "we expect", "we anticipate", "we believe", "we estimate" and other phrases of similar meaning. For example, the statements regarding capitalizing on growth opportunities in the pharmacy business, expanding retail locations and dispensing activity and controlling costs all involve forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those contemplated in the forward-looking statements. Such factors include, but are not limited to: 1) The continuing opportunities for acquisitions, establishment of FQHC relationships and success in consolidation of administration and elimination of overhead; and 2) Changes in capital equity markets. Additional factors are described under "Part I. Item 1. A. - Risk Factors" in our most recent Quarterly Report on Form 10-Q and under "Part I. Item 1. A. - Risk Factors" in our most recent Annual Report on Form 10-K as filed with the Securities and Exchange Commission. Except as required by law, Nyer Medical Group undertakes no obligation to release publicly the result of any revision to these forward- looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Nyer Medical Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Health WorldNet, Inc. Launches New Web Portal for Health & Medical Resources
2. C5 Medical Werks Joins in Sponsoring SpineWeek 2008 in Geneva, Switzerland
3. Ohio State University Medical Center to Test Efficacy of Hyperbaric Oxygen Medicine on Stroke Victims
4. Rep. Boozman, AOA Officials Tour Military Eye Care Facilities at Walter Reed Army Medical Center
5. US Air Force Medical Service Selects Shipcom Wireless for Major Healthcare RFID Contract
6. Intelligent Medical Objects (IMO), Inc. announces the General Availability of Its Terminology Portal Service for EMR/EHR and Charge-Capture Applications
7. SAGE acquires 2 new medical journals
8. Spirus Medical Announces 510(k) Clearance from FDA for Expanded Use of Endo-Ease(R) Discovery SB(TM)
9. John Mackey, Chairman and CEO of Whole Foods Market(R), and Ellen M. Zane, President and CEO, Tufts Medical Center and the Floating Hospital for Children, Offer Advice to Bentley Students at May 17 Commencement
10. Law Offices of Howard G. Smith Announces 24 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Inverness Medical Innovations, Inc.
11. Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... ... Family Dermatology has recently joined their multi-specialty medical group. The dermatology practice ... cosmetic services. , “We’re excited to add this excellent dermatology practice to our ...
(Date:1/20/2017)... ... ... A new partnership between Goodwill® and Roadie, Inc. aims to make it easier ... couches to dressers and bicycles. Roadie — the national on-the-way delivery network — will ... through February 28th. , “January is an exciting time when resolutions are made ...
(Date:1/20/2017)... ... January 20, 2017 , ... Lice Troopers, the lice removal company based ... school-aged children since the holiday season. , “It happens every year around this ... hugs and taking photos, which is the head-to-head gateway that lice need to spread.” ...
(Date:1/20/2017)... ... 20, 2017 , ... Vitamin Well has launched two new ... have been produced in collaboration with Zlatan Ibrahimovic and have been developed to ... a successful launch in Sweden last year, the next generation sports drinks VW+001 ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... ... vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in a study ... Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive Expiratory Pressure ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... -- Report Details What can be expected ... to grow at the fastest rates? This visiongain report ... opportunities and prospects. Our 190-page report provides 124 ... in the industry and the future market prospects. Our ... all the major categories of the ophthalmic devices market. ...
(Date:1/19/2017)... 19, 2017 This report on the opioid ... scenario of the global market. Large number of chronic ... chronic constipation is a major side effect of consumption ... novel targeted therapy has been prescribed to treat opioid ... targeted medicines, and growing awareness about the therapy are ...
(Date:1/19/2017)... 2017 Accuray Incorporated (Nasdaq: ARAY ... continue to set the bar for excellence in customer ... user satisfaction rating among radiation treatment delivery systems in ... Market Intelligence Briefing™. The most recent ratings trend also ... industry peers for 11 of the past 12 quarters. ...
Breaking Medicine Technology: